New drug combo aims to outsmart resistant lung cancer
NCT ID NCT07710612
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This phase 2 trial tests whether adding an experimental drug called ABSK043 to the standard targeted therapy osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutated, PD-L1 positive). The study enrolls adults whose cancer has spread or cannot be surgically removed. Researchers will monitor safety, side effects, and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABSK043 combined with osimertinib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with EGFR-mutated lung cancer that has stopped responding to standard therapy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits and risks are not yet fully known. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER WITH EGFR-MUTATED AND PD-L1 POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact